Loading…
Based on limited metadata, ARJ Infusion Services Inc received an FDA Warning Letter on April 2, 2018, regarding their infusion services operations. Without access to the full letter text or detailed subject information, the specific regulatory violations cannot be precisely characterized, though infusion service providers are typically subject to FDA oversight related to compounding, sterility, quality control, and product safety. The issuing office and exact violation count are not specified in the available metadata. A review of the complete Warning Letter would be necessary to identify the particular compliance issues cited by the FDA.